Amzerin Mounia, Mokrim Maha, Errihani Hassan, Piccart Martine J
Department of Medical Oncology, National Institute of Oncology, Université Mohammed V de Rabat, Avenue Allal El Fassi, 10100, Rabat, Morocco.
Department of Medical Oncology, Jules Bordet Institute, Université Libre de Bruxelles, Boulevard de Waterloo 125, B-1000, Brussels, Belgium.
J Med Case Rep. 2015 Feb 12;9:5. doi: 10.1186/1752-1947-9-5.
Pegylated irinotecan NKTR-102 is a topoisomerase I inhibitor-polymer conjugate. This new formulation of irinotecan has been evaluated in a phase II clinical trial and is showing remarkable activity. To the best of our knowledge, this is the first case report of an impressive iterative response to pegylated irinotecan NKTR-102 in metastatic breast cancer.
We report the case of a 49-year-old Caucasian woman diagnosed with metastatic luminal A breast cancer with initial bone followed by liver and bone marrow metastases, treated with three lines of hormonal therapy, targeted therapy and six lines of chemotherapy. She showed no major response to conventional treatment, whereas, the tumor shrinkage under pegylated irinotecan NKTR-102 was impressive, durable and iterative.
Reintroduction of an active drug is a valid approach as illustrated by our case. The results of the current phase III trials of pegylated irinotecan NKTR-102 are eagerly awaited.
聚乙二醇化伊立替康NKTR-102是一种拓扑异构酶I抑制剂-聚合物偶联物。这种伊立替康的新制剂已在一项II期临床试验中进行了评估，并显示出显著活性。据我们所知，这是首例关于转移性乳腺癌患者对聚乙二醇化伊立替康NKTR-102产生显著反复应答的病例报告。
我们报告了一名49岁白种女性的病例，该患者被诊断为转移性腔面A型乳腺癌，最初转移至骨，随后转移至肝和骨髓，接受了三线激素治疗、靶向治疗以及六线化疗。她对传统治疗无明显应答，然而，在聚乙二醇化伊立替康NKTR-102治疗下肿瘤缩小显著、持久且反复。
如我们的病例所示，重新使用活性药物是一种有效的方法。我们急切期待聚乙二醇化伊立替康NKTR-102当前III期试验的结果。
